Rebuilding the Damaged Heart: Mesenchymal Stem Cells, Cell-Based Therapy, and Engineered Heart Tissue
- 1 July 2016
- journal article
- review article
- Published by American Physiological Society in Physiological Reviews
- Vol. 96 (3), 1127-1168
- https://doi.org/10.1152/physrev.00019.2015
Abstract
Mesenchymal stem cells (MSCs) are broadly distributed cells that retain postnatal capacity for self-renewal and multilineage differentiation. MSCs evade immune detection, secrete an array of anti-inflammatory and anti-fibrotic mediators, and very importantly activate resident precursors. These properties form the basis for the strategy of clinical application of cell-based therapeutics for inflammatory and fibrotic conditions. In cardiovascular medicine, administration of autologous or allogeneic MSCs in patients with ischemic and nonischemic cardiomyopathy holds significant promise. Numerous preclinical studies of ischemic and nonischemic cardiomyopathy employing MSC-based therapy have demonstrated that the properties of reducing fibrosis, stimulating angiogenesis, and cardiomyogenesis have led to improvements in the structure and function of remodeled ventricles. Further attempts have been made to augment MSCs' effects through genetic modification and cell preconditioning. Progression of MSC therapy to early clinical trials has supported their role in improving cardiac structure and function, functional capacity, and patient quality of life. Emerging data have supported larger clinical trials that have been either completed or are currently underway. Mechanistically, MSC therapy is thought to benefit the heart by stimulating innate anti-fibrotic and regenerative responses. The mechanisms of action involve paracrine signaling, cell-cell interactions, and fusion with resident cells. Trans-differentiation of MSCs to bona fide cardiomyocytes and coronary vessels is also thought to occur, although at a nonphysiological level. Recently, MSC-based tissue engineering for cardiovascular disease has been examined with quite encouraging results. This review discusses MSCs from their basic biological characteristics to their role as a promising therapeutic strategy for clinical cardiovascular disease.Keywords
Funding Information
- Foundation for the National Institutes of Health (FNIH) (R01 HL110737, R01 HL107110, 5UM HL113460, R01 HL084275, 5UM HL113460)
- Starr Foundation
- Soffer Family Foundation
This publication has 101 references indexed in Scilit:
- Intramyocardial Injection of Autologous Bone Marrow-Derived Ex Vivo Expanded Mesenchymal Stem Cells in Acute Myocardial Infarction Patients is Feasible and Safe up to 5 Years of Follow-upJournal of Cardiovascular Translational Research, 2013
- Cardiomyocyte proliferation and progenitor cell recruitment underlie therapeutic regeneration after myocardial infarction in the adult mouse heartEMBO Molecular Medicine, 2013
- Pluripotent stem cell-derived cardiac tissue patch with advanced structure and functionBiomaterials, 2011
- Direct injection of autologous mesenchymal stromal cells improves myocardial functionBiochemical and Biophysical Research Communications, 2009
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial InfarctionJournal of the American College of Cardiology, 2009
- Allogeneic Mesenchymal Precursor Cell Therapy to Limit Remodeling After Myocardial Infarction: The Effect of Cell DosageThe Annals of Thoracic Surgery, 2009
- Endothelial differentiation of Wharton's jelly–derived mesenchymal stem cells in comparison with bone marrow–derived mesenchymal stem cellsExperimental Hematology, 2009
- Macrophage roles following myocardial infarctionInternational Journal of Cardiology, 2008
- Pre-Treatment of Mesenchymal Stem Cells With a Combination of Growth Factors Enhances Gap Junction Formation, Cytoprotective Effect on Cardiomyocytes, and Therapeutic Efficacy for Myocardial InfarctionJournal of the American College of Cardiology, 2008
- Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancerInternational Journal of Cancer, 2004